ABIVAX Société Anonyme (LON:0RA9)
68.30
-0.30 (-0.44%)
At close: Aug 29, 2025
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 4.01M EUR in the half year ending December 31, 2024, with 78.20% growth. This brings the company's revenue in the last twelve months to 10.59M, up 128.98% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
10.59M EUR
Revenue Growth
+128.98%
P/S Ratio
512.70
Revenue / Employee
153.45K EUR
Employees
69
Market Cap
4.54B GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 671.60M |
ABIVAX Société Anonyme News
- 3 days ago - How Hedge Funds Won Big on an Obscure Drugmaker - WSJ
- 6 days ago - 2 Logical Mid-Cap Biotech Buyout Targets - Seeking Alpha
- 25 days ago - Earnings Outlook For Abivax - Benzinga
- 5 weeks ago - Abivax Announces Closing of $747.5 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing ... - GuruFocus
- 5 weeks ago - Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) - GlobeNewsWire
- 5 weeks ago - Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst - Seeking Alpha
- 5 weeks ago - Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares - GlobeNewsWire